Skip to content
value.today

Fibrocell Science, Inc.

Total raised
$113 M
10 rounds on record
Latest round
$3 M
Jul 2018
First round on record
Oct 2009
Today
Private
No later event on record

Funding rounds

10 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Fibrocell Science, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2018$3 MNo. 10$2 to $10 million

Fibrocell Science, Inc.: Raise no. 10, Jul 2018

Investors in this round

3 investors had bought by the notice of Jul 17, 2018: 3 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$8,384
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John M. Maslowski · Executive Officer, Director · President and Chief Executive Officer
  • Christine E. St.Clare · Director
  • Douglas J. Swirsky · Director · Chairman of the Board
  • Julian P. Kirk · Director
  • Kelvin D. Moore · Director
  • Marc B. Mazur · Director
  • Marcus E. Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in FL, IL, NJ, TX, and outside the US

Remarks in the notice

  • On fees: “H.C. Wainwright received the above sales commissions in connection with the private placement of warrants. It also received the HCW Warrants in connection with a registered direct offering by the Company.”
  • On the amounts: “"The warrants and underlying shares of common stock include warrants (i) to purchase 958,152 shares of common stock issued to certain institutional investors and (ii) to purchase 103,186 shares of common stock issued to H.C. Wainwright (""HCW Warrants"")"”

Signed by John M. Maslowski, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jul 17, 2018. Read the notice at the SEC.

optionsSEC
May 2018$5 MNo. 9$2 to $10 million

Fibrocell Science, Inc.: Raise no. 9, May 2018

Investors in this round

4 investors had bought by the notice of Jun 13, 2018: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$13,376
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John M. Maslowski · Executive Officer, Director · President and Chief Executive Officer
  • Christine E. St.Clare · Director
  • Douglas J. Swirsky · Director · Chairman of the Board
  • Julian P. Kirk · Director
  • Kelvin D. Moore · Director
  • Marc B. Mazur · Director
  • Marcus E. Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in CA, IL, NJ, NY, and outside the US

Remarks in the notice

  • On fees: “H.C. Wainwright received the above sales commissions in connection with the private placement of warrants. It also received the HCW Warrants in connection with a registered direct offering by the Company.”
  • On the amounts: “"The warrants and underlying shares of common stock include warrants (i) to purchase 1,528,668 shares of common stock issued to certain institutional investors and (ii) to purchase 142,676 shares of common stock issued to H.C. Wainwright (""HCW Warrants"")"”

Signed by John M. Maslowski, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jun 13, 2018. Read the notice at the SEC.

optionsSEC
Aug 2016$18 MNo. 8$10 to $50 million

Fibrocell Science, Inc.: Raise no. 8, Aug 2016

Investors in this round

14 investors had bought by the notice of Aug 24, 2016: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$18 M of $25 M offered; $7 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • Rule 506(c): may be advertised publicly; every buyer must be a verified accredited investor
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pernock · Executive Officer, Director · Chairman of the Board and Chief Executive Officer
  • John F. Maslowski · Executive Officer · Senior Vice President, Scientific Affairs
  • Keith A. Goldan · Executive Officer · Senior Vice President, Chief Financial Officer and Treasurer
  • Michael F. Marino · Executive Officer · Senior Vice President, General Counsel and Corporate Secretary
  • Christine E. St.Clare · Director
  • Douglas J. Swirsky · Director
  • Julian F. Kirk · Director
  • Kelvin F. Moore · Director
  • Marc F. Mazur · Director
  • Marcus E. Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael F. Marino, Senior VP, General Counsel and Corporate Sec.. Source: SEC Form D, newest notice filed Aug 24, 2016. Read the notice at the SEC.

debt, optionsSEC
Oct 2012$45 MNo. 7$10 to $50 million

Fibrocell Science, Inc.: Raise no. 7, Oct 2012

Investors in this round

114 investors had bought by the notice of Oct 15, 2012: 114 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$45 M of $45 M offered
Smallest investment taken
$1,500
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$2,700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pernock · Executive Officer, Director
  • Declan Daly · Executive Officer, Director
  • Julian Kirk · Director
  • Kelvin Moore · Director
  • Marc Mazur · Director
  • Marcus Smith · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • John Carris Investments LLC (CRD 145767) · New York, New YorkSold in all US states, and outside the US
  • Barclays (CRD 19714) · New York, New YorkSold in MA, NJ, NY, TX, VT
  • MTS Securities, LLC (CRD 104059) · New York, New YorkSold in CA, CT, IL, MA, NY, VA

Signed by David Pernock, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 15, 2012. Read the notice at the SEC.

equitySEC
May 2012$3 MNo. 6$2 to $10 million

Fibrocell Science, Inc.: Raise no. 6, May 2012

Investors in this round

63 investors had bought by the notice of May 18, 2012: 63 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $12 M offered; $9 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$1,200,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pernock · Executive Officer, Director
  • Declan Daly · Executive Officer, Director
  • George J. Korkos · Director
  • Kelvin J. Moore · Director
  • Marc Mazur · Director
  • Robert Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • John Thomas Financial Inc. (CRD 40982) · New York, New YorkSold in all US states, and outside the US
  • John Carris Investments LLC (CRD 145767) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “Assumes sale of total offering amount. Excludes (i) 3% expense allowance and (ii) warrants to purchase shares of common stock.”
  • On the amounts: “Total Offering Amount includes $3,000,000 over-subscription amount.”

Signed by David Pernock, Chief Executive Officer. Source: SEC Form D, newest notice filed May 18, 2012. Read the notice at the SEC.

equity, optionsSEC
Aug 2011$23 MNo. 5$10 to $50 million

Fibrocell Science, Inc.: Raise no. 5, Aug 2011

Investors in this round

75 investors had bought by the notice of Aug 18, 2011: 75 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $23 M offered
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$1,595,664
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pernock · Executive Officer, Director
  • Declan Daly · Executive Officer, Director
  • George J. Korkos · Director
  • Kelvin Moore · Director
  • Marc Mazur · Director
  • Robert Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Gleacher & Company Securities, Inc. (CRD 298) · New York, New YorkSold in all US states, and outside the US
  • John Carris Investments (CRD 145767) · New York, New YorkSold in all US states, and outside the US
  • Rodman & Renshaw, LLC (CRD 16415) · New York, New YorkSold in all US states, and outside the US

Remarks in the notice

  • On fees: “The placement agents will be issued five-year warrants to purchase a number of shares of common stock equal to 3% of the gross proceeds of the offering divided by the trailing volume weighted average price for the five days proceeding the closing date.”

Signed by David Pernock, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 18, 2011. Read the notice at the SEC.

equity, optionsSEC
Dec 2010$4 MNo. 4$2 to $10 million

Fibrocell Science, Inc.: Raise no. 4, Dec 2010

Investors in this round

67 investors had bought by the notice of Feb 3, 2011: 67 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $8 M offered; $4 M still to sell
Smallest investment taken
$5,000
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
$343,440
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pernock · Executive Officer, Director
  • Declan Daly · Executive Officer, Director
  • George J. Korkos · Director
  • Kelvin Moore · Director
  • Marc Mazur · Director
  • Robert Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • John Carris Investments LLC (CRD 145767) · broker-dealer John Carris Investments LLC (CRD 145767) · New York, New YorkSold in all US states, and outside the US

Signed by Declan Daly, Chief Financial Officer, Chief Operating Officer& Controller. Source: SEC Form D, newest notice filed Feb 3, 2011. Read the notice at the SEC.

optionsSEC
Jul 2010$3 MNo. 3$2 to $10 million

Fibrocell Science, Inc.: Raise no. 3, Jul 2010

Investors in this round

20 investors had bought by the notice of Aug 4, 2010: 20 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $3 M offered
Smallest investment taken
$15,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$216,160
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pernock · Executive Officer, Director
  • Declan Daly · Executive Officer, Director
  • George Korkos · Director
  • Kelvin Moore · Director
  • Marc Mazur · Director
  • Paul Hopper · Director
  • Robert Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Viriathus Capital · broker-dealer John Carris Investments LLC (CRD 145767) · New York, New YorkSold in AZ, CA, CT, FL, IL, LA, NJ, NY, VA
  • John Carris Investments LLC (CRD 145767) · New York, New YorkSold in AZ, CA, CT, FL, IL, LA, NJ, NY, VA

Remarks in the notice

  • On fees: “$216,160 in cash plus Warrants to purchase 360,267 shares of Common Stock at $0.60 per share”

Signed by Declan Daly, Cfo. Source: SEC Form D, newest notice filed Aug 4, 2010. Read the notice at the SEC.

equity, optionsSEC
Mar 2010$4 MNo. 2$2 to $10 million

Fibrocell Science, Inc.: Raise no. 2, Mar 2010

Investors in this round

23 investors had bought by the notice of Mar 29, 2010: 23 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
$4,575
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$304,600
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Pernock · Executive Officer, Director
  • Declan Daly · Executive Officer, Director
  • Kelvin Moore · Director
  • Paul Hopper · Director
  • Robert Langer · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • John Carris Investments LLC (CRD 145767) · New York, NySold in no state named
  • Viriathus Capital · broker-dealer John Carris Investments LLC (CRD 145767) · New York, NySold in no state named

Remarks in the notice

  • On fees: “$304,600 in cash plus Warrants to purchase 406,133 shares of Common Stock at $0.75 per share”

Signed by Declan Daly, Cfo. Source: SEC Form D, newest notice filed Mar 29, 2010. Read the notice at the SEC.

equity, optionsSEC
Oct 2009$5 MNo. 1$2 to $10 million

Fibrocell Science, Inc.: Raise no. 1, Oct 2009

Investors in this round

11 investors had bought by the notice of Mar 29, 2010: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
$50,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
$1 million to $5 million
Sales commissions
$325,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Declan Daly · Executive Officer, Director
  • David Pernock · Director
  • Kelvin Moore · Director
  • Paul Hopper · Director
  • Robert Langor · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Viriathus Capital · broker-dealer John Carris Investments LLC (CRD 145767) · New York, NySold in no state named
  • John Carris Investments LLC (CRD 145767) · New York, NySold in no state named

Remarks in the notice

  • On fees: “$325,000 in cash plus Warrants to purchase 250,000 shares at $1.30 share”

Signed by Declan Daly, Ceo. Source: SEC Form D, newest notice filed Mar 29, 2010. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Fibrocell Science, Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2018).

    SEC Form D · Jul 2018

  • Revenue range over time, as stated in its notices: revenue between $1 million and $5 million in 2010; revenue of up to $1 million in 2011; revenue of up to $1 million in 2012.

    SEC Form D (revenue range) · Oct 2012

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2018

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Fibrocell Science, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 10 rounds above had up to 114 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Fibrocell Science, Inc.
NameRoleNamed in
John M. MaslowskiPresident and Chief Executive OfficerJul 2018
David PernockChairman of the Board and Chief Executive OfficerAug 2016
John F. MaslowskiSenior Vice President, Scientific AffairsAug 2016
Keith A. GoldanSenior Vice President, Chief Financial Officer and TreasurerAug 2016
Michael F. MarinoSenior Vice President, General Counsel and Corporate SecretaryAug 2016
Declan DalyExecutive officerOct 2012
Christine E. St.ClareDirectorJul 2018
Douglas J. SwirskyChairman of the BoardJul 2018
John M. MaslowskiPresident and Chief Executive OfficerJul 2018
Julian P. KirkDirectorJul 2018
Kelvin D. MooreDirectorJul 2018
Marc B. MazurDirectorJul 2018
Marcus E. SmithDirectorJul 2018
David PernockChairman of the Board and Chief Executive OfficerAug 2016
Julian F. KirkDirectorAug 2016
Kelvin F. MooreDirectorAug 2016
Marc F. MazurDirectorAug 2016
Declan DalyDirectorOct 2012
Julian KirkDirectorOct 2012
Kelvin MooreDirectorOct 2012
Marc MazurDirectorOct 2012
Marcus SmithDirectorOct 2012
George J. KorkosDirectorMay 2012
Kelvin J. MooreDirectorMay 2012
Robert LangerDirectorMay 2012
George KorkosDirectorAug 2010
Paul HopperDirectorAug 2010
Robert LangorDirectorMar 2010